Swedish Orphan ADR (SWTUY) 12.4500 $SWTUY
Psoriatic Arthritis Pipeline Report 2015 - 28 Companies & 25 Drug Profiles
M2 - Fri Jul 10, 3:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9fbkq/psoriatic) has announced the addition of the "Psoriatic Arthritis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AbGenomics International, Inc. - Alder Biopharmaceuticals Inc. - Amgen Inc. - Avesthagen Limited - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Coherus BioSciences, Inc. - Covagen AG - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Innovent Biologics, Inc. - Johnson & Johnson - Kineta, Inc. - Mabion SA - Momenta Pharmaceuticals, Inc. - Novartis AG - Oncobiologics, Inc. - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Swedish Orphan Biovitrum AB - Therapeutic Proteins International, LLC - UCB S.A. Drug Profiles - abatacept (recombinant) - AbGn-168H - ABT-122 - adalimumab biosimilar - anakinra (recombinant) - apremilast - bimekizumab - brodalumab - clazakizumab - COVA-322 - dalazatide - etanercept biosimilar - golimumab - golimumab biosimilar - guselkumab - IBI-303 - IBPM-004AM - IBPM-005IX - infliximab biosimilar - INV-17 - itolizumab - ixekizumab - Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis - secukinumab - tofacitinib For more information visit http://www.researchandmarkets.com/research/s9fbkq/psoriatic
PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), MNTA: 21.76 (+0.49), CHRS: 33.06 (+3.19), JNJ: 99.53 (+1.13), ALDR: 49.86 (+3.96), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14)
Psoriatic Arthritis Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jul 09, 8:30PM CDT
The report "Psoriatic Arthritis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Psoriatic Arthritis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/psoriatic-ar...eport.html .
JNJ: 99.53 (+1.13), ALDR: 49.86 (+3.96), PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), NVS: 103.22 (+3.20), CHRS: 33.06 (+3.19), CELGZ: 2.15 (+0.14)
Resolutions from Sobi's Annual General Meeting
Thomson Reuters ONE - Tue Jun 30, 9:16AM CDT
The Swedish Orphan Biovitrum AB (publ) (Sobi) Annual General Meeting (AGM) convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including:
European Commission approves Orfadin(R) oral suspension
Thomson Reuters ONE - Mon Jun 29, 1:00AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the European Commission has approved the oral suspension formulation of Orfadin(R) (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) as of 19 June 2015. HT-1 is a rare genetic disease that affects infants and children. It is progressive and may result in liver and kidney failure and can be fatal if untreated.
Invitation - Presentation of Sobi's second quarter 2015
Thomson Reuters ONE - Fri Jun 26, 1:30AM CDT
On 16 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the second quarter 2015.
Sobi's 2012 Long-Term Incentive programme meets all objectives
Thomson Reuters ONE - Fri Jun 12, 1:00AM CDT
Swedish Orphan Biovitrum AB's (publ) (Sobi) Board of Directors today announced that the company's 2012 Long-Term Incentive programme met the objectives set and has vested in full. The total number of shares awarded to Sobi employees enrolled in the 2012 programme is 583,139.
Sobi Board of Directors terminates discussions regarding non-binding proposal
Thomson Reuters ONE - Mon Jun 08, 1:01AM CDT
On 27 April 2015 the Board of Swedish Orphan Biovitrum AB (publ) (Sobi) confirmed that it had received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company. The Board of Directors of Sobi has terminated discussions regarding this proposal. Sobi will continue to focus on preparations for the upcoming planned launch of Elocta and Alprolix and on building value through its diverse and growing portfolio.
Sobi's partner Biogen submits marketing authorisation application for Alprolix(R) (rFIXFc) in Europe
Thomson Reuters ONE - Thu Jun 04, 7:31AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that partner Biogen has submitted a Marketing Authorisation Application (MAA) for Alprolix (rFIXFc) to the European Medicines Agency (EMA). Sobi has an opt-in right to assume final development and commercialisation of Alprolix in Europe, Russia, certain countries in the Middle East, and North Africa. The MAA filing with the EMA coupled with the receipt of the opt-in data package, triggers the formal opt-in right, for Sobi to exercise its option in accordance with the collaboration agreement.
Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
Thomson Reuters ONE - Wed May 27, 1:03AM CDT
The shareholders in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, are hereby summoned to the annual general meeting (the "Meeting"
, to be held on Tuesday 30 June 2015 at 2.00 p.m. in Wallenbergsalen at Kungliga Ingenjorsvetenskapsakademien (IVA), Grev Turegatan 16, Stockholm, Sweden.
Idiopathic Juvenile Arthritis (Still's Disease) Therapeutics Pipeline Review 2015
M2 - Wed May 06, 8:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vkzw3z/idiopathic) has announced the addition of the "Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaMab Co., Ltd - Biocon Limited - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - Mabion SA - Oncodesign SA - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Swedish Orphan Biovitrum AB - UCB S.A. For more information visit http://www.researchandmarkets.com/research/vkzw3z/idiopathic
PFE: 34.36 (+0.50)
Sobi publishes its Report for the First Quarter 2015
Thomson Reuters ONE - Wed May 06, 1:33AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the first quarter 2015. Revenues for the quarter totalled SEK 865 M (573). All parts of the business contributed to the result with ReFacto(R), Orfadin(R) and Kineret(R) delivering strong performance.
Early treatment and a longer life - new Orfadin formats meet new patient needs
Thomson Reuters ONE - Mon May 04, 7:31AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the oral suspension formulation and the 20 mg capsule of Orfadin (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease that affects infants and children; it is progressive in nature, may result in liver and kidney failure and can be fatal if untreated.
Invitation - Presentation of Sobi's first quarter 2015
Thomson Reuters ONE - Thu Apr 30, 1:00AM CDT
On 6 May, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the first quarter 2015.
Sobi's Board of Directors postpones Annual General Meeting of Shareholders
Thomson Reuters ONE - Wed Apr 29, 1:06AM CDT
On 27 April 2015 the Board of Directors of Swedish Orphan Biovitrum AB (publ) (Sobi) confirmed that it had received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company. There can be no certainty that an offer will be made, nor as to the terms of any such offer.
Statement regarding recent speculation
Thomson Reuters ONE - Mon Apr 27, 1:06AM CDT
The Board of Swedish Orphan Biovitrum AB (publ) notes the recent speculation in the press and elsewhere regarding a potential acquisition of the company.
Swedish Orphan Biovitrum AB (publ) : Sobi publishes Annual Report 2014
Thomson Reuters ONE - Wed Apr 15, 6:01AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today published its Annual Report for 2014, themed "We have a story to tell", on the company's website, www.sobi.com.
Sobi publishes its Report for the Fourth Quarter and Full Year 2014
Thomson Reuters ONE - Thu Feb 19, 1:02AM CST
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the fourth quarter and full year 2014. Revenues for the year totalled SEK 2,607 M (2,177), an increase of 20 per cent. Revenues in the fourth quarter were 15 per cent higher compared to the previous year. All parts of the business contributed to the result with Orfadin(R) and the Partner Products portfolio delivering strong performance.
Invitation - Presentation of Sobi's fourth quarter and full year results 2014
Thomson Reuters ONE - Thu Feb 12, 1:00AM CST
On 19 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the fourth quarter and full year 2014.
BioSpecifics Technologies wins approval for XIAPEX in the EU for treating Peyronie's Disease
M2 - Tue Feb 03, 5:16AM CST
Biopharmaceutical company BioSpecifics Technologies (NasdaqGM:BSTC) reported on Monday the receipt of approval by the Swedish Orphan Biovitrum AB (Sobi) from the EU Commission to market XIAPEX for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees.
BSTC: 50.96 (-0.51)
Psoriatic Arthritis Pipeline Report 2015 - 28 Companies & 25 Drug Profiles
M2 - Fri Jul 10, 3:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9fbkq/psoriatic) has announced the addition of the "Psoriatic Arthritis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Psoriatic Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psoriatic Arthritis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - AbGenomics International, Inc. - Alder Biopharmaceuticals Inc. - Amgen Inc. - Avesthagen Limited - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Coherus BioSciences, Inc. - Covagen AG - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - Innovent Biologics, Inc. - Johnson & Johnson - Kineta, Inc. - Mabion SA - Momenta Pharmaceuticals, Inc. - Novartis AG - Oncobiologics, Inc. - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Swedish Orphan Biovitrum AB - Therapeutic Proteins International, LLC - UCB S.A. Drug Profiles - abatacept (recombinant) - AbGn-168H - ABT-122 - adalimumab biosimilar - anakinra (recombinant) - apremilast - bimekizumab - brodalumab - clazakizumab - COVA-322 - dalazatide - etanercept biosimilar - golimumab - golimumab biosimilar - guselkumab - IBI-303 - IBPM-004AM - IBPM-005IX - infliximab biosimilar - INV-17 - itolizumab - ixekizumab - Peptide to Inhibit CD44 for Rheumatoid and Psoriatic Arthritis - secukinumab - tofacitinib For more information visit http://www.researchandmarkets.com/research/s9fbkq/psoriatic
PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), MNTA: 21.76 (+0.49), CHRS: 33.06 (+3.19), JNJ: 99.53 (+1.13), ALDR: 49.86 (+3.96), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14)
Psoriatic Arthritis Therapeutic Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - Thu Jul 09, 8:30PM CDT
The report "Psoriatic Arthritis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Psoriatic Arthritis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/psoriatic-ar...eport.html .
JNJ: 99.53 (+1.13), ALDR: 49.86 (+3.96), PFE: 34.36 (+0.50), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38), NVS: 103.22 (+3.20), CHRS: 33.06 (+3.19), CELGZ: 2.15 (+0.14)
Resolutions from Sobi's Annual General Meeting
Thomson Reuters ONE - Tue Jun 30, 9:16AM CDT
The Swedish Orphan Biovitrum AB (publ) (Sobi) Annual General Meeting (AGM) convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including:
European Commission approves Orfadin(R) oral suspension
Thomson Reuters ONE - Mon Jun 29, 1:00AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the European Commission has approved the oral suspension formulation of Orfadin(R) (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1) as of 19 June 2015. HT-1 is a rare genetic disease that affects infants and children. It is progressive and may result in liver and kidney failure and can be fatal if untreated.
Invitation - Presentation of Sobi's second quarter 2015
Thomson Reuters ONE - Fri Jun 26, 1:30AM CDT
On 16 July, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the second quarter 2015.
Sobi's 2012 Long-Term Incentive programme meets all objectives
Thomson Reuters ONE - Fri Jun 12, 1:00AM CDT
Swedish Orphan Biovitrum AB's (publ) (Sobi) Board of Directors today announced that the company's 2012 Long-Term Incentive programme met the objectives set and has vested in full. The total number of shares awarded to Sobi employees enrolled in the 2012 programme is 583,139.
Sobi Board of Directors terminates discussions regarding non-binding proposal
Thomson Reuters ONE - Mon Jun 08, 1:01AM CDT
On 27 April 2015 the Board of Swedish Orphan Biovitrum AB (publ) (Sobi) confirmed that it had received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company. The Board of Directors of Sobi has terminated discussions regarding this proposal. Sobi will continue to focus on preparations for the upcoming planned launch of Elocta and Alprolix and on building value through its diverse and growing portfolio.
Sobi's partner Biogen submits marketing authorisation application for Alprolix(R) (rFIXFc) in Europe
Thomson Reuters ONE - Thu Jun 04, 7:31AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that partner Biogen has submitted a Marketing Authorisation Application (MAA) for Alprolix (rFIXFc) to the European Medicines Agency (EMA). Sobi has an opt-in right to assume final development and commercialisation of Alprolix in Europe, Russia, certain countries in the Middle East, and North Africa. The MAA filing with the EMA coupled with the receipt of the opt-in data package, triggers the formal opt-in right, for Sobi to exercise its option in accordance with the collaboration agreement.
Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ)
Thomson Reuters ONE - Wed May 27, 1:03AM CDT
The shareholders in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, are hereby summoned to the annual general meeting (the "Meeting"
, to be held on Tuesday 30 June 2015 at 2.00 p.m. in Wallenbergsalen at Kungliga Ingenjorsvetenskapsakademien (IVA), Grev Turegatan 16, Stockholm, Sweden. Idiopathic Juvenile Arthritis (Still's Disease) Therapeutics Pipeline Review 2015
M2 - Wed May 06, 8:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vkzw3z/idiopathic) has announced the addition of the "Idiopathic Juvenile Arthritis (Still's Disease) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Juvenile Arthritis (Still's Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlphaMab Co., Ltd - Biocon Limited - Epirus Biopharmaceuticals, Inc. - Genor BioPharma Co., Ltd. - Mabion SA - Oncodesign SA - Panacea Biotec Limited - Pfizer Inc. - Sandoz International GmbH - Swedish Orphan Biovitrum AB - UCB S.A. For more information visit http://www.researchandmarkets.com/research/vkzw3z/idiopathic
PFE: 34.36 (+0.50)
Sobi publishes its Report for the First Quarter 2015
Thomson Reuters ONE - Wed May 06, 1:33AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the first quarter 2015. Revenues for the quarter totalled SEK 865 M (573). All parts of the business contributed to the result with ReFacto(R), Orfadin(R) and Kineret(R) delivering strong performance.
Early treatment and a longer life - new Orfadin formats meet new patient needs
Thomson Reuters ONE - Mon May 04, 7:31AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the oral suspension formulation and the 20 mg capsule of Orfadin (nitisinone) for the treatment of Hereditary Tyrosinaemia type-1 (HT-1). HT-1 is a rare genetic disease that affects infants and children; it is progressive in nature, may result in liver and kidney failure and can be fatal if untreated.
Invitation - Presentation of Sobi's first quarter 2015
Thomson Reuters ONE - Thu Apr 30, 1:00AM CDT
On 6 May, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the first quarter 2015.
Sobi's Board of Directors postpones Annual General Meeting of Shareholders
Thomson Reuters ONE - Wed Apr 29, 1:06AM CDT
On 27 April 2015 the Board of Directors of Swedish Orphan Biovitrum AB (publ) (Sobi) confirmed that it had received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company. There can be no certainty that an offer will be made, nor as to the terms of any such offer.
Statement regarding recent speculation
Thomson Reuters ONE - Mon Apr 27, 1:06AM CDT
The Board of Swedish Orphan Biovitrum AB (publ) notes the recent speculation in the press and elsewhere regarding a potential acquisition of the company.
Swedish Orphan Biovitrum AB (publ) : Sobi publishes Annual Report 2014
Thomson Reuters ONE - Wed Apr 15, 6:01AM CDT
Swedish Orphan Biovitrum AB (publ) (Sobi) today published its Annual Report for 2014, themed "We have a story to tell", on the company's website, www.sobi.com.
Sobi publishes its Report for the Fourth Quarter and Full Year 2014
Thomson Reuters ONE - Thu Feb 19, 1:02AM CST
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced its results for the fourth quarter and full year 2014. Revenues for the year totalled SEK 2,607 M (2,177), an increase of 20 per cent. Revenues in the fourth quarter were 15 per cent higher compared to the previous year. All parts of the business contributed to the result with Orfadin(R) and the Partner Products portfolio delivering strong performance.
Invitation - Presentation of Sobi's fourth quarter and full year results 2014
Thomson Reuters ONE - Thu Feb 12, 1:00AM CST
On 19 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi) will publish its report for the fourth quarter and full year 2014.
BioSpecifics Technologies wins approval for XIAPEX in the EU for treating Peyronie's Disease
M2 - Tue Feb 03, 5:16AM CST
Biopharmaceutical company BioSpecifics Technologies (NasdaqGM:BSTC) reported on Monday the receipt of approval by the Swedish Orphan Biovitrum AB (Sobi) from the EU Commission to market XIAPEX for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees.
BSTC: 50.96 (-0.51)
